(NASDAQ: HCM) Hutchmed's forecast annual revenue growth rate of 4.07% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Hutchmed's revenue in 2024 is $837,999,000.On average, 2 Wall Street analysts forecast HCM's revenue for 2024 to be $603,604,601,343, with the lowest HCM revenue forecast at $582,434,816,495, and the highest HCM revenue forecast at $624,774,386,192. On average, 2 Wall Street analysts forecast HCM's revenue for 2025 to be $707,398,232,045, with the lowest HCM revenue forecast at $680,712,523,751, and the highest HCM revenue forecast at $734,084,811,595.
In 2026, HCM is forecast to generate $825,217,346,181 in revenue, with the lowest revenue forecast at $770,626,170,815 and the highest revenue forecast at $879,809,392,803.